DEXamethasone twice for pain treatment of Total Knee Arthroplasty (DEX-2-TKA)
A randomized blinded placebo-controlled clinical trial
09-03-2020: Last patient included, Inclusion complete, Næstved Hospital is stopping inclusion
03-03-2020: One patient to go
13-01-2020: Bispebjerg Hospital is stopping including patients
10-12-2019: Less than 40 patients to go, Odense University Hospital is stopping including patients
29-11-2019: Gildhøj Private Hospital is stopping including patients
25-10-2019: Less than 100 patients to go
06-10-2019: 75% of all patients icluded.
01-10-2019: Zealand University Hospital Køge is stopping including patients
05-9-2019:66% og all patients included. Only one third to go.
03-09-2019: First patient at Gildhøj Private Hospital
14-08-2019: 60% of all patients included.
27-06-2019: DEX-2-TKA is cleared to start up at Gildhøj Private Hospital by GCP-unit
05-06-2019: 50% of all patients included.
29-04-2019: 40% of all patients included.
25-02-2019: 25% of all patients inculded.
14-01-2019: First patient at Zealand University Hospital Køge
20-12-2018: First patient at Odense University Hospital
07-12-2018: DEX-2-TKA is cleared to start up at Zealand University Hospital Køge by GCP-unit
30-10-2018: DEX-2-TKA is cleared to start up at Odense University Hospital by GCP-unit
08-10-2018: First patient at Næstved Hospital
02-10-2018: First patient at Bispebjerg Hosptial
24-09-2018: DEX-2-TKA is cleared to start up at Bispebjerg Hospital by GCP-unit
10-09-2018: DEX-2-TKA is cleared to start up at Næstved Hospital by GCP-unit
Webmaster: Daniel Hägi-Pedersen
Copyright © All Rights Reserved.